Lapatinib
- CAS No.
- 231277-92-2
- Chemical Name:
- Lapatinib
- Synonyms
- Tykerb;Tyverb;CS-220;GW-2016;CS-1860;GW 57201;Rapatini;lapatinib;GSK572016;GW-572016
- CBNumber:
- CB8855402
- Molecular Formula:
- C29H26ClFN4O4S
- Molecular Weight:
- 581.06
- MOL File:
- 231277-92-2.mol
- Modify Date:
- 2024/7/31 20:31:10
| Melting point | 144-146oC |
|---|---|
| Boiling point | 750.7±60.0 °C(Predicted) |
| Density | 1.381±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C(protect from light) |
| solubility | Soluble in DMSO (up to 200 mg/ml) |
| form | solid |
| pka | 6.34±0.19(Predicted) |
| color | Yellow |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
| InChIKey | BCFGMOOMADDAQU-UHFFFAOYSA-N |
| SMILES | N1=C2C(C=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C2)=C(NC2=CC=C(OCC3=CC=CC(F)=C3)C(Cl)=C2)N=C1 |
| CAS DataBase Reference | 231277-92-2(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H319-H362-H413 | |||||||||
| Precautionary statements | P201-P260-P263-P273-P305+P351+P338-P308+P313 | |||||||||
| HS Code | 29349990 | |||||||||
| NFPA 704 |
|
Lapatinib Chemical Properties,Uses,Production
Description
Lapatinib, a new member of the 4-anilinoquinazoline class of RTK inhibitors
(RTKIs), was launched as an oral treatment for breast cancer.
Lapatinib has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated
in combination with capecitabine for treating patients with advanced or
metastatic breast cancer whose tumors overexpress HER2 and who have
received prior therapy including an anthracycline, a taxane, and trastuzumab.
Previously marketed drugs from the 4-anilinoquinazoline class include
erlotinib (Tarceva) and gefitinib (IressaTM), both of which are indicated for
treating non-small-cell lung cancer (NSCLC). As with erlotinib and gefitinib, To Market, To Market 2007 475 lapatinib is an ATP-competitive kinase inhibitor. It inhibits the tyrosine kinase activity EGFR and HER-2 with apparent Ki values of 3 and 13 nM, respectively, and has slow off-rate kinetics (t1/2X300 min).
In addition, dividing the daily dose of lapatinib results in approximately 2-fold higher exposure at steady state compared to the same total dose administered once daily.
The chemical synthesis of lapatinib entails the condensation of 4-chloro-6-iodoquinazoline and 3-chloro-4-(3-fluorobenzyloxy)aniline to produce a diaryl amine intermediate followed by Stille coupling of the iodo group with 5-dioxolanyl-2-(tributylstannyl)furan and subsequent acid hydrolysis of the cyclic ketal to the corresponding aldehyde. Finally, reductive amination of the aldehyde intermediate with 2-(methanesulfonyl) ethylamine in the presence of sodium triacetoxyborohydride produces lapatinib.
.
Uses
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. It is a antineoplastic which is used in breast cancer research and a tyrosine kinase inhibitor. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2)
General Description
Class: receptor tyrosine kinase
Treatment: HER2-positive breast cancer
Elimination half-life = 24 h
Protein binding = 99%
Lapatinib Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Jigs Chemical ltd | +919099003427 | Gujarat, India | 239 | 58 | Inquiry |
| Bulat Pharmaceutical Pvt Ltd | +91-8448085659 +91-8448085660 | Haryana, India | 123 | 58 | Inquiry |
| Laxai Life Sciences | +91-4023480125 +91-4023480125 | Hyderabad, India | 21 | 58 | Inquiry |
| Sakar Healthcare | +91-8976292690 +91-9967572302 | Gujarat, India | 47 | 58 | Inquiry |
| Mac Chem Products (India) Pvt Ltd (Naprod Group) | +91-9727753234 +91-7770016606 | Maharashtra, India | 37 | 58 | Inquiry |
| Shreyaa Medilife Private Limited | +91-6354474696 +91-9879513108 | Ahmedabad, India | 67 | 58 | Inquiry |
| Akums Lifesciences Ltd | +91-1147511000 +91-1147511000 | New Delhi, India | 38 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| BTS Synergy Private Limited | 08047304689 | Delhi, India | 1 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
Related articles
- Synthesis and Bioactivity of Lapatinib
- Lapatinib is an oral tyrosine kinase inhibitor of small molecule epidermal growth factor (EGFR: ErbB-1, ErbB-2).
- Jul 19，2022
231277-92-2(Lapatinib)Related Search:
1of4
chevron_right